ProGen launches PharmaSynth manufacturing unit
Biotechnology firm ProGen Pharmaceuticals has spun-out its manufacturing operations as the new wholly-owned subsidiary PharmaSynth.
Archives for July 2, 2008
Thermo expands RNAi offering with Open Bio purchase
Laboratory industry heavyweight, Thermo Fisher Scientific has acquired shRNA expert Open Biosystems to expand its gene silencing offering.
Patheon to offer cytotoxic services through BSP deal
Contract research and production specialist Patheon is to promote BSP Pharmaceuticals' cytotoxic development and manufacturing services as part of a marketing agreement that the two firms have signed.
Sinclair and Wockhardt strike deal
UK-based Sinclair Pharmaceuticals has entered into a manufacturing and distribution agreement with Wockhardt, an Indian pharmaceutical and biotech company.
Researchers improve siRNA delivery
The delivery of siRNA into cells has taken a step forward according to research published in the Journal of the American Chemical Society.
Agilent buys Nano Instruments to bolster materials science unit
Agilent Technologies has continued its push into the materials science market with the acquisition of nanoindentation instrument manufacturer Nano Instruments.
Symbio enters, BASi exits Phase I scene
This week one North American contract research organisation (CRO) has entered the Phase I clinical trials market, while another has exited the scene.
Binto eliminating the detective work from clinical trials
A service provider called Binto is filling a much needed vacuum in the clinical trial industry in terms of patient tracking, eliminating the need for big pharmaceutical firms to resort to methods such as hiring private investigators to track down "lost"...
Pharmaceutical facility news in brief
in-PharmaTechnologist.com's periodic round-up of developments in the field of pharmaceutical facilities includes news of two environmental fines, MHRA plant approval and a strike at Teva.
Qiagen acquires rotary RT-PCR cycler inventor
Dutch sample and assay expert, Qiagen has bought Australia-based Corbett Life Science Pty in a deal that could be worth up to $135m (€86m).